Assembly Biosciences, Inc. (ASMB) Stock Price & Analysis
Assembly Biosciences, Inc. (ASMB) rose 0.73% to USD 22.72 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
ASMB last closed at USD 22.56; the session ranged USD 22.2–23.82 on volume of 239,416 shares. Market capitalization is $450.25M, with a 52-week range of USD 15.84–39.71 (NMS). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 22.72 |
|---|---|
| Change | ▲ 0.73% (up) |
| Previous Close | USD 22.56 |
| Open | USD 23.37 |
| Day Range | USD 22.2 – 23.82 |
| 52-Week Range | USD 15.84 – 39.71 |
| Volume | 239,416 shares |
| Market Cap | $450.25M |
| Exchange | NMS |
Technical Analysis (ASMB)
Nexqual's technical model rates ASMB "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.01 (neutral) |
| vs SMA50 | Below (USD 27.92) |
| MACD | -1.47 (negative) |
Analyst Ratings (ASMB)
Wall Street analysts rate ASMB "Strong Buy" based on 4 analysts, with a mean price target of USD 48.75 (range USD 40–62), per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 48.75 |
| High Target | USD 62 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ASMB)
| EPS Estimate | USD -0.53 |
|---|---|
| Revenue Estimate | $8.60M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.54 vs est -0.64 ▲ beat |
| 2025-12-31 | USD 2.48 vs est -0.85 ▲ beat |
| 2025-09-30 | USD -0.72 vs est -0.65 ▼ miss |
| 2025-06-30 | USD -1.33 vs est -1.73 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (ASMB)
| Total Revenue | $71.10M |
|---|---|
| Revenue Growth (YoY) | -12.80% |
| Gross Margin | +8.77% |
| Operating Margin | -138.44% |
| Profit Margin | -8.98% |
| ROE | -5.66% |
| Debt / Equity | 1.25 |
| Current Ratio | 6.65 |
| Total Cash | $226.60M |
| Total Debt | $2.49M |
| Free Cash Flow | $-16.56M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (ASMB)
Nexqual rates Assembly Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Strong — Revenue +154% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $227M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$17M, burning cash |
| Efficiency | Critical — ROE -6%, ROA -5.1% |
Ownership (ASMB)
| Insider Ownership | +28.42% |
|---|---|
| Institutional Ownership | +48.36% |
| Shares Outstanding | 19.82M |
| Float | 8.80M |
| Short % of Float | +11.41% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (ASMB)
Assembly Biosciences, Inc. is led by Jason A. Okazaki (age 49), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| CEO, President & Director | Jason A. Okazaki (age 49) |
|---|---|
| Chief Scientific Officer | William E. Delaney IV (age 53) |
| Principal Financial Officer, Executive Director of Accounting & Treasury | Jeanette M. Bjorkquist (age 38) |
| Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | Shannon Ryan |
Major Backers & Investors (ASMB)
Notable institutional backers of Assembly Biosciences, Inc. include Gilead Sciences Inc, Farallon Capital Management LLC, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 02:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Gilead Sciences Inc | 28.35% |
| Farallon Capital Management LLC | 7.72% |
| RA Capital Management, L.P. | 6.42% |
| Commodore Capital Lp | 6.29% |
| Janus Henderson Group PLC | 5.34% |
| Paradigm Biocapital Advisors LP | 4.19% |
| Parkman Healthcare Partners LLC | 2.59% |
| Point72 Asset Management, L.P. | 2.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.21% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
From Assembly Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
- Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
- The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses.
- It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| NXTC | NextCure, Inc. | USD 2.33 | ▼ 21.02% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
| ATRA | Atara Biotherapeutics, Inc. | USD 9.77 | ▼ 1.51% |
| APRE | Aprea Therapeutics, Inc. | USD 0.74 | ▼ 0.34% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.